MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.67
-0.69
-1.67%
Closed 16:11 08/11 EDT
OPEN
41.32
PREV CLOSE
41.36
HIGH
42.10
LOW
40.51
VOLUME
244.94K
TURNOVER
--
52 WEEK HIGH
76.69
52 WEEK LOW
36.20
MARKET CAP
1.81B
P/E (TTM)
-13.0445
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average QURE stock price target is 73.93 with a high estimate of 91.00 and a low estimate of 56.00.

EPS

QURE News

More
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -100.00% and -91.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 14:25
uniQure Q2 EPS $(0.96) Down From $(0.83) YoY
uniQure (NASDAQ:QURE) reported quarterly losses of $(0.96) per share. This is a 15.66 percent decrease over losses of $(0.83) per share from the same period last year.
Benzinga · 07/30 12:35
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~~ Completed First Patient Dosing in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~LEX
GlobeNewswire · 07/30 11:05
A Quick Investment Idea On uniQure
Seeking Alpha · 07/30 04:00
uniQure EPS misses by $0.31, misses on revenue
Seeking Alpha · 07/30 04:00
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
Annexon Initiates $100 Million IPO Effort
Seeking Alpha - Article · 07/11 15:00
Were Hedge Funds Right About Piling Into Uniqure NV (QURE)?
Insider Monkey · 07/08 17:38

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-0.89%

Hot Stocks

Symbol
Price
%Change

About QURE

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
More

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.